Abstracts tagged "prognostic factors"

Abstract Number: 0814 • ACR Convergence 2024
Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Xinzhuang Yang², Yu Fang Ding³, qian wang¹, Jiuliang Zhao¹, Weida Liu⁴, Yongtai Liu⁵, Zhuang Tian⁵, Yanhong Wang⁶, Xiaojian Wang⁷, Mengtao Li¹ and Xiaofeng Zeng⁸, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ²Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), ⁴State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁶Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes…
Abstract Number: 2247 • ACR Convergence 2024
Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis
Klára Prajzlerová¹, Olga Kryštufková², Petra Hánová¹, Nora Růžičková², Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 0037 • ACR Convergence 2024
Clonal Haematopoiesis of Indeterminate Potential (CHIP) Is Associated with Disease Activity in Rheumatoid Arthritis
Athena Chin¹, Sue Branford², Annabelle Small³, katie Lowe³, malcolm Smith⁴, Monika Kutyna⁵, Robert King², Susanna Proudman⁶, Devendra Hiwase⁷ and Mihir Wechalekar⁸, ¹Royal Adelaide Hospital, Tranmere, South Australia, Australia, ²SA Pathology, Adelaide, Australia, ³Flinders University, Adelaide, Australia, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵South Australian Health and Medical Research Institute, Adelaide, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Clonal haematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations in genes that are known to drive haematological…
Abstract Number: 1133 • ACR Convergence 2024
Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators
Maria F. Elizondo-Benitez¹, Iris Jazmín Colunga Pedraza², jose Ramon Azpiri-Lopez³, Dionicio Galarza-Delgado⁴, Jesus Cardenas-de la Garza⁵, Rosa Icela Arvizu-Rivera², Andrea Guajardo Aldaco² and Valeria Gonzalez-Gonzalez⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory, and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients. Nail psoriasis affects 80% of…
Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef Smolen¹, Gerd Burmester², Yoshiya Tanaka³, Tsutomu Takeuchi⁴, Jeffrey Curtis⁵, Ted Mikuls⁶, Clementina López Medina⁷, Peter C. Taylor⁸, Nicola Tilt⁹, Bernard Lauwerys¹⁰, Baran Ufuktepe¹¹ and Thomas Huizinga¹², ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Reina Sofia University Hospital, Cordoba, Spain, ⁸University of Oxford, Oxford, United Kingdom, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Istanbul, Turkey, ¹²Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
shiri keret¹, Raisa Silva², Irada Choudhuri², Eugenia Gkiaouraki³, Tanya Chandra⁴, Nantakarn Pongtarakulpanit⁵, shreya Sriram³, silvia Martinez Laverde³, Dana Ascherman³, Siamak Mogahadam⁵, Chester Oddis⁵ and Rohit Aggarwal⁶, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
Abstract Number: 1158 • ACR Convergence 2024
Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Sehreen Mumtaz¹, Megan Sullivan², Maximiliano Diaz Menindez³, Emily Craver⁴ and Florentina Berianu⁵, ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵mayo clinic, Ponte Vedra Beach, FL
Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
Abstract Number: 2297 • ACR Convergence 2024
Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry
Olga Rusinovich¹, Zulema Plaza², Mónica Fernández Castro³, José Rosas-Gómez de Salazar⁴, Victor Manuel Martinez Taboada⁵, Alejandro Olive⁶, Raúl Menor Almagro⁷, Belen Serrano Benavente⁸, Judit Font Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesus A García-Vadillo¹², Ruth Lopez Gonzalez¹³, Javier Narvaez-García¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Gonzalez Martin¹⁷, Paloma Vela-Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, MARIA BEATRIZ PAREDES ROMERO²¹, ELENA Aurrecoechea²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Heredia Martin²⁵, Clara Moriano²⁶, Maria Angeles Blazquez Canamero²⁷, Paula Estrada-Alarcón²⁸, enrique Judez²⁹, Joaquin María Belzunegui:³⁰, Consuelo Ramos³¹, Marta de la Puerta³², Fernando Sánchez-Alonso³³ and Jose Luis Andreu³⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Cantabria, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Hospital Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ¹²H La Princesa, Madrid, Spain, ¹³Complejo Hospitalario de Zamora, Zamora, Castilla y Leon, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵H Universitario de Canarias, La Laguna- Tenerife, Canarias, Spain, ¹⁶Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁷H Madrid Norte SanChinarro, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ²⁰Gob Canarias, Tenerife, Canarias, Spain, ²¹H Infanta Sofia, Madrid, Spain, ²²HOSPITAL SIERRALLANA, CANTABRIA, Spain, ²³12 de Octubre University Hospital, Madrid, Spain, ²⁴Galicia Health Service (SERGAS), Vigo, Spain, ²⁵Hospital de L’Hospitalet, Barcelona, Spain, ²⁶Hospital León, LEON, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²⁸Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁹H de Albacete, Albacete, Spain, ³⁰H de Donostia, Donostia-San Sebasti, Spain, ³¹Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Spanish Society of Rheumatology, Madrid, Spain, ³³Sociedad Española de Reumatología, Madrid, Spain, ³⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: It remains debated if patients with Sjögren´s disease (SjD) have a greater mortality risk. The objective of our study was to determine the magnitude…
Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
Abstract Number: 1202 • ACR Convergence 2024
Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression
Afshin Jamshidi¹, Osvaldo Espin-Garcia², Thomas G. Wilson³, Ian Loveless³, Jean-Pierre Pelletier¹, Amanda Ali⁴ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Department of Epidemiology and Biostatistics, University of Western Ontario; Dalla Lana School of Public Health and Department of Statistical Sciences, University of Toronto; Department of Biostatistics, Schroeder Arthritis Institute; Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, ⁴Henry Ford Health + Michigan State University Health Sciences; Center for Molecular Medicine and Genetics, Wayne State University, Montreal, QC, Canada
Background/Purpose: The development of knee osteoarthritis (OA) is generally characterized by a slow evolution. However, its progression and severity may occur rapidly in some individuals.…
Abstract Number: 2379 • ACR Convergence 2024
Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
Liying Chen¹, Ou Deng², Ruichen Cong², Dingqi Lu³, Ting Fang¹, Mei Chen¹, Runrun Zhang⁴ and Xinchang Wang³, ¹Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), ²Graduate School of Human Sciences, Waseda University, Mikajima, Japan, ³Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), ⁴The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic)
Background/Purpose: Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease marked by unpredictable flares. However, no flare risk prediction model has been developed for Asian…
Abstract Number: 0554 • ACR Convergence 2023
A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge³, Stan Kamp³, Nancy Redinger³, Teresa Aberle³, Eliza Chakravarty³, Cristina Arriens⁴, Yanfeng Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane L. Kamen⁶, Jill Buyon⁸, Judith James³ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University School of Medicine, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked by varied disease activity, underscored by complex immune dysregulation, including altered immune mediators and…
Abstract Number: 1268 • ACR Convergence 2023
Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup
Tetsuji Sawada¹, Susumu Nishiyama², Shohei Yamashita³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³Tokyo Medical University Hospital, Shinjuku, Japan, ⁴NHO Sagamihara National Hospital, Kanagawa, Japan, ⁵NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…

« Previous Page
1
…
4
5
6
7
8
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].